Citadel Advisors
IBIO icon

Citadel Advisors’s iBio IBIO Stock Holding History

Citadel Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$55 – 14960
2023
Q4 		$55 Sell
40
-931
-96% -$4.07K ﹤0.01% 14147
2023
Q3 		$5.9K Sell
971
-90
-8% -$778 ﹤0.01% 13359
2023
Q2 		$12.9K Buy
1,061
+865
+441% +$16.3K ﹤0.01% 13059
2023
Q1 		$8.17K Sell
196
-170
-46% -$4.38K ﹤0.01% 13675
2022
Q4 		$3.25K Sell
366
-6
-2% -$203 ﹤0.01% 14235
2022
Q3 		$32K Sell
372
-109
-23% -$15K ﹤0.01% 11867
2022
Q2 		$64K Buy
481
+68
+16% +$10.2K ﹤0.01% 11772
2022
Q1 		$88K Buy
413
+3
+0.7% +$628 ﹤0.01% 12398
2021
Q4 		$112K Buy
410
+165
+67% +$62.9K ﹤0.01% 12603
2021
Q3 		$130K Sell
245
-231
-49% -$144K ﹤0.01% 12548
2021
Q2 		$359K Buy
476
+64
+16% +$46.7K ﹤0.01% 10831
2021
Q1 		$317K Sell
412
-1
-0.2% -$871 ﹤0.01% 10730
2020
Q4 		$217K Sell
413
-49
-11% -$39.9K ﹤0.01% 9616
2020
Q3 		$469K Buy
+462
New +$670K ﹤0.01% 7409

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors's IBIO Position: Q1 2026 in Review

Citadel Advisors opened a new position in iBio (IBIO) in Q1 2026: 956,429 shares worth $1.82M. The stake represents ﹤0.01% of the portfolio and ranks #6281 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IBIO as recently as Q3 2025.

Citadel Advisors first reported a position in IBIO in Q3 2013 and has held it in 28 quarters since. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Citadel Advisors held 956,429 shares of iBio worth $1.82M as of Q1 2026.
  • iBio was a new Citadel Advisors position in Q1 2026.
  • iBio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6281 holding.
  • Citadel Advisors first reported a position in iBio in Q3 2013 and has held it in 28 quarters since.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.